Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03020069 · ClinicalTrials.gov registry record · NA

Use of Continuous Glucose Monitoring System With Intensive Feedback in Adolescents With Poorly Controlled Type 1 Diabetes

A NA study of Type 1 Diabetes, sponsored by NYU Langone Health.

Completed
Registry status
NA
Development phase
13
Enrollment target
1
Study location

NCT03020069 is a NA study of Type 1 Diabetes that has completed, run by NYU Langone Health. The registered enrollment target is 13 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03020069, a NA study of Type 1 Diabetes, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
NA
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine that continuous glucose monitoring systems (CGMS) with intensive real time feedback about diabetes management from medical staff to the patient will affect motivation and/or behavior, in adolescents with poorly controlled type 1 diabetes. The investigators hypothesize that short-term CGMS use with feedback (and/or lack thereof) and patients' sense of self-efficacy will influence their stage of change and potentially glucose levels.

Conditions Studied

Interventions

  • DEVICE CGMS Device
  • OTHER No Device

Study Locations (1)

New York

  • New York University Medical Center - New York

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2015-11
Est. Completion 2018-07-13
Phase NA

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT03020069

The ClinicalTrials.gov registry entry for NCT03020069 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (98% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which CGMS Device is the first listed.

NCT03020069 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03020069 about?

NCT03020069 is a clinical study titled "Use of Continuous Glucose Monitoring System With Intensive Feedback in Adolescents With Poorly Controlled Type 1 Diabetes". The purpose of this study is to determine that continuous glucose monitoring systems (CGMS) with intensive real time feedback about diabetes management from medical staff to the patient will affect motivation and/or behavior, in adolescents with poorly controlled type 1 diabetes. The investigators h...

What is the current status of trial NCT03020069?

This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2015-11. Estimated completion is 2018-07-13.

What conditions does trial NCT03020069 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT03020069?

The interventions under investigation include: CGMS Device (DEVICE), No Device (OTHER).

Who is sponsoring clinical trial NCT03020069?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03020069 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.